Shafee et al., 2008 - Google Patents
Cancer stem cells contribute to cisplatin resistance in Brca1/p53–mediated mouse mammary tumorsShafee et al., 2008
View HTML- Document ID
- 2443427060914334768
- Author
- Shafee N
- Smith C
- Wei S
- Kim Y
- Mills G
- Hortobagyi G
- Stanbridge E
- Lee E
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
The majority of BRCA1-associated breast cancers are basal cell–like, which is associated with a poor outcome. Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more …
- 201000011510 cancer 0 title abstract description 53
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shafee et al. | Cancer stem cells contribute to cisplatin resistance in Brca1/p53–mediated mouse mammary tumors | |
| Coates et al. | Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer | |
| Li et al. | Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses | |
| Giambra et al. | Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling | |
| Hurley et al. | 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer | |
| Yamamoto et al. | PIK3CA mutation is an early event in the development of endometriosis‐associated ovarian clear cell adenocarcinoma | |
| LaFave et al. | Loss of BAP1 function leads to EZH2-dependent transformation | |
| Parasramka et al. | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma | |
| Lehmann et al. | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors | |
| Cleary et al. | Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers | |
| Velu et al. | Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity | |
| Bellone et al. | Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro | |
| Gilder et al. | The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres | |
| Stearns et al. | c-Myc overexpression causes anaplasia in medulloblastoma | |
| Lacerda et al. | Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model | |
| Shan et al. | Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer | |
| Thomas et al. | Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers | |
| Yu et al. | Prostate cancer stem cell biology | |
| Groeneweg et al. | Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth | |
| Turrell et al. | Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse | |
| Dienstmann et al. | Molecular predictors of response to chemotherapy in colorectal cancer | |
| Miller et al. | Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer | |
| Harris et al. | CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance | |
| Moroney et al. | Inhibiting Wnt/beta‐catenin in CTNNB1‐mutated endometrial cancer | |
| Yin et al. | FUBP1 promotes colorectal cancer stemness and metastasis via DVL1‐mediated activation of Wnt/β‐catenin signaling |